. 2016 Jun 1;6:27082. doi: 10.1038/srep27082

Table 2. Summary of studies on the use of intravitreal ranibizumab for ROP.

Authors	Study design	Sample size	Criteria for treatment with anti-VEGF	Initial regression	Recurrence rate	Subsequent Treatment	Complications
Castellanos et al.²²	Retrospective	6 eyes of 3 infants	Type 1 ROP	100%	0%	–	–
Chen et al.²³	Retrospective	31 eyes of 16 infants(ranibizumab) 41 eyes of 21 infants (bevacizumab)	Type 1 ROP	100% (ranibizumab) 98% (bevacizumab)	0%	Laser	–
Wong et al.²⁹	Retrospective	6 eyes of 4 infants (ranibizumab) 4 eyes of 2 infants (bevacizumab)	Zone 1 or posterior Zone2 disease	100% (both ranibizumab + bevacizumab)	83% ranibizumab 0% bevacizumab	Laser	–
Erol et al.²⁴	Retrospective	15 eyes of 8 infants (ranibizumab) 21 eyes of 12 infants (bevacizumab)	Type 1 ROP	100% (both ranibizumab + bevacizumab)	40% ranibizumab 10% bevacizumab	Laser	–
Mota et al.²⁷	Retrospective	4 eyes of 2 infants	APROP	Case 1: bilateral ranibizumab injection → initial bilateral regression then recurrence at 4 weeks → 2^nd injection + laser → regress Case 2: initial laser therapy → disease progression → ranibizumab + supplementary laser → regress			–
Lin et al.²⁶	Retrospective	2 eyes of 1 infant	Zone 1 Stage 3 Plus	Bilateral bevacizumab injection → initial regression → recurrence at 2 months → laser + ranibizumab → regress			–
Jang et al.²⁸	Retrospective	2 eyes of 1 infant	Zone 1 Stage 3 Plus	Initial combined bilateral ranibizumab with laser → regress → bilateral recurrence with total retinal detachment at 4 months			–
Present series	Retrospective	10 eyes of 6 infants	Selected cases of Type 1 ROP, eg APROP, poor pupil dilatation	63%^* (70%^)	60%^* (43%^)	Laser, surgery in 1 case	Non–progressive peripheral lens opacity

^*Only including eyes with intravitreal ranibizumab as initial therapy.

^{^}Also including eyes with laser as initial therapy followed by intravitreal ranibizumab.